Financial Report - Amgen

Amgen

1Q Revenues: $6.2 billion (+11%)
1Q Earnings: $1.8 billion (-8%)
Comments: Growth across newer products, including Otezla, Repatha, MVASI, KANJINTI and Evenity, partially offset declines in several products from the impact of biosimilar and generic competition. Enbrel sales were $1.2 billion. Prolia sales were $654 million in the quarter, up 10%. Aranesp sales were $422 million, up 2%. Repatha sales were $229 million, up 62%. Evenity sales reached $100 million in the quarter. Otezla sales were $479 million. KYPROLIS sales were $280 million, up 14%. XGEVA sales were $481 million, up 2%. Vectibix sales were $202 million, up 19%. Nplate sales were $218 million, up 15%. Neulasta sales were down 40% to $609 million. NEUPOGEN sales were down 11% to $65 million. EPOGEN sales were down 29% to $155 million. Sensipar/Mimpara sales were down 42% to $123 million.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.